IARS
Isoleucine--tRNA ligase, cytoplasmic
Protein Summary
Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAS, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Isoleucine-tRNA synthetase belongs to the class-I aminoacyl-tRNA synthetase family and has been identified as a target of autoantibodies in the autoimmune disease polymyositis/dermatomyositis. Alternatively spliced transcript variants have been found. [provided by RefSeq, Nov 2012]
- ENST00000375643
- ENSP00000364794
- ENSG00000196305
- IRS
- ILRS
- IARS1
- ILERS
- GRIDHH
- PRO0785
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
interacting protein | 1 | ||
disease perturbation | 0.99 | ||
kinase perturbation | 0.99 | ||
protein domain | 0.97 | ||
co-expressed gene | 0.95 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 260.88 (req: < 5)
Gene RIFs: 5 (req: <= 3)
Antibodies: 125 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 260.88 (req: >= 5)
Gene RIFs: 5 (req: > 3)
Antibodies: 125 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 8
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 15
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1